Bio-Rad Laboratories (FRA:BUWA) Growth Rank: 2 (As of Sep. 09, 2026) — 60% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
70 GF Score
Price €326.20
GF Value €276.95
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Growth Rank?

Bio-Rad Laboratories FRA:BUWA -0.43% 70 Growth Rank is 2 as of Sep. 09, 2026, which is 60% below its 10-year median of 5.00. GuruFocus rates FRA:BUWA with a GF Score™ of 70/100 and a GF Value™ of €276.95 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Bio-Rad Laboratories has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Bio-Rad Laboratories Growth Rank Related Terms

FRA:BUWA vs PODD, GKOS, GMED: Growth Rank Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Growth Rank distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Growth Rank falls into.


FRA:BUWA
70GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Bio-Rad Laboratories (FRA:BUWA) has a Growth Rank of 2 as of Sep. 09, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Bio-Rad Laboratories and its competitors. This is 60% below median its historical median of 5.00. Over the past decade, Bio-Rad Laboratories' Growth Rank has ranged from 1.00 to 9.00.
Is Bio-Rad Laboratories' Growth Rank too high?
Bio-Rad Laboratories' current Growth Rank of 2 is 60% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Bio-Rad Laboratories has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Growth Rank compare to PODD and GKOS?
Bio-Rad Laboratories' Growth Rank of 2 can be compared against companies in the Medical Devices & Instruments industry. Historically, Bio-Rad Laboratories' own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Growth Rank is 2, which is 60% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €276.95, compared to a current price of €326.20 — trading 17.8% above its estimated fair value. The current Growth Rank is 2, which is 60% below median its 10-year median of 5.00. Bio-Rad Laboratories' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Growth Rank is 2 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of €326.20 is trading 17.8% above its estimated GF Value™ of €276.95. GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.

Key valuation signals for FRA:BUWA:

  • Growth Rank: 2 (60% below median its 10-year median of 5.00)
  • GF Value™: €276.95 vs. price of €326.20 (17.8% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
70GF Score

Get the complete analysis for FRA:BUWA

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€326.20
Price
€276.95
GF Value